Thymulin

Also known as: Thymalin, Facteur Thymique Serique, FTS-Zn

A thymic hormone that regulates immune function and T-cell maturation.

Overview

Thymulin (also known as Thymalin in some formulations) is a nonapeptide hormone produced by thymic epithelial cells. It requires zinc for biological activity and plays a crucial role in T-cell differentiation and immune regulation. Used in Russia for immune support and anti-aging.

Mechanism of Action

Binds to specific receptors on T-cell precursors, promoting differentiation and maturation. Requires zinc as cofactor. Modulates cytokine production and immune cell function. Levels decline with thymic involution during aging.

Pharmacokinetics

Short half-life. Requires zinc for activity. Subcutaneous or intramuscular administration.

Dosing Protocols

Note: These are research protocols from literature. This is not medical advice.

1

Immune Support

Dose

10-20 mg

Frequency

Daily

Duration

10 days

Often given as course 2x yearly

Stacking Recommendations

Peptides that may be combined based on complementary mechanisms in research settings.

Rationale: Comprehensive immune support

Synergy: Multiple thymic peptide pathways

Research Areas

Immune FunctionImmunosenescenceT-Cell MaturationAutoimmune DiseaseAnti-AgingInfection Prevention

Key Research Findings

  • 1Essential for T-cell development
  • 2Levels decline significantly with age
  • 3Zinc-dependent activity
  • 4Used in Russian geroprotective protocols

Side Effects & Contraindications

Reported Side Effects

  • Generally well-tolerated
  • Rare allergic reactions

Contraindications

  • Autoimmune disease (use cautiously)
  • Zinc deficiency (correct first)

Safety Considerations

Generally well-tolerated. Requires adequate zinc status. May affect autoimmune conditions. Limited Western clinical data.

Storage Requirements

Refrigerate 2-8°C

Scientific References

Quick Reference

Sequence
pGlu-Ala-Lys-Ser-Gln-Gly-Gly-Ser-Asn (zinc-bound)
Molecular Weight
857 g/mol
Half-Life
Short
Bioavailability
Injectable
Research Stage
clinical phase 2
Administration
Subcutaneous or intramuscular